The gene encoding a novel protein designated nm23-H1, which was recently identified as identical to the A subunit of nucleotide diphosphate kinase from human erythrocytes, has been proposed to play a role in tumor metastasis suppression. We report that untreated neuroblastoma tumors contain a cellular polypeptide (M, = 19,000) designated p19, identified in two-dimensional electrophoretic gels, which occurs at significantly higher levels (P = 0.0001) in primary tumors containing amplified N-myc gene. The partial amino acid sequence obtained for pl9 is identical to the sequence ofthe human nm23-H1 protein.
Introduction
The discovery in cancer cells of alterations in genes that normally regulate cellular growth and development has encouraged the search for genes that may be responsible for promoting or suppressing tumor spread and metastasis. The protein product ofthe nm23-Hl gene has been proposed as a candidate tumor metastasis suppressor protein (1, 2) . A strong association was reported between reduced expression ofthe nm23-H 1 gene and acquisition of metastatic behavior. In model systems of rodent metastasis, nm23 RNA levels were lower in highly metastatic cells compared with tumor cells of low metastatic potential (3) . Tumors from patients with infiltrating ductal breast carcinomas with lymph node metastasis had low nm23 RNA content (4) . Nm23-Hl protein has substantial homology with the polypeptide product of a Drosophila gene, designated awd (5) (6) (7) , and with a protein in Dictyostelium discoideum, designated GiPI7, which exhibits nucleoside diphosphate kinase (NDP)' activity (8) . It has recently been shown that the A subunit ofNDP kinase in human red cells is identical to nm23-Hi, on the basis of sequence analysis (9) .
Neuroblastoma is a common childhood tumor that originates in neural-crest derived cells (10) . Children with the tumor present with local, regional, or metastatic disease. In clinical studies of neuroblastoma, amplification of the N-myc oncogene has been found to be significantly associated with advanced stage disease and rapid tumor progression (1 1 
Methods
Tumors and cell lines. Tumors were obtained from patients at the time of surgery and represented all clinical stages of the disease, from local-ized (stage I) to metastatic disease (stage IV). Of the 40 tumors studied for their content ofp 19, 4 belonged to the special group ofinfants with metastatic disease (stage IV-S) associated with a very good outcome (10) . N-myc gene copy number was determined as previously described (1 1). The stage IV-S tumors did not show N-mycgene amplification. 15 neuroblastoma cell lines were also analyzed for their p19/nm23 content by 2-D PAGE. 5 cell lines had a nonamplified and 10 had an amplified N-myc gene (25-150 copies).
2-D PAGE. Samples of 200 ,g oftumor tissue, or of2 x 106 cells from neuroblastoma cell lines, were solubilized by addition of (per liter) 8 M urea, 20 ml of NP-40 surfactant, 20 ml of ampholytes (pH 3.5-10), 20 ml of2-mercaptoethanol, and 0.2 mM ofPMSFin distilled deionized water. 2-D PAGE was done as previously described (13) . In most cases 20-30-,gl aliquots containing 70 ,g ofprotein were immediately applied onto isofocusing gels. First-dimension gels contained 50 ml of ampholytes per liter (pH 3.5-10). Isofocusing was done at 1,200 V for 16 h and 1,500 V for the last 2 h. 20 gels were run simultaneously. For the second-dimension separation, an acrylamide gradient of 1 1.4-14.0 g/dl was used. Protein spots in gels were visualized using a silverstaining technique (14) .
Quantification ofpl9/nm23. Spot detection and quantitation were performed as previously described (15) . Each gel was scanned in a 1,024 X 1,024 pixel format, giving 160 um as the pixel width. The digitized images were assigned coded numbers and were analyzed for the presence and quantity of pl9/nm23, without knowledge of the sample to which a gel image corresponded. Pl9/nm23 was identified based on its characteristic migration and position in relation to neighboring landmark spots that were present in all gels included in this study and that were recognizable to the analyst. The pl9/nm23 spot, as well as 20 other reference spots, were quantified by placing a cursor on each spot on the graphics monitor and typing in the name for the spot. The integrated intensity of each spot was measured in units of optical density times square millimeter. Data on these spots were analyzed using the Michigan Interactive Data Analysis System, a statistical software package. The 20 reference spots were used to adjust the pl9/nm23 spot integrated intensity as previously described ( 15), to compensate for any variability in protein loading or staining between gels. For comparison of spot intensities between groups, the rank-based KruskalWallis statistic was used rather than parametric tests that require the assumption of Gaussian distributions.
Results
Relationship between pl9 levels and N-myc gene copy number and stage of the disease. Table I ) and the other with 125 copies (B; patient 10, Table I ), exhibiting a difference in the level of p19. N-myc gene copy number was determined as previously described (3) . Phosphorylated forms (Opl8a and Opl8b) of a polypeptide, designated Op18, which are diminished with N-myc gene amplification are labeled as a reference ( 12 (15) . There was minimal overlap between the amplified and 8 nonamplified groups. Only one tumor in the nonamplified 7 group had a level for p19 that was above the mean for the amplified group. The tumor belonged to the metastatic stage 6 (6.11)
IV. In the amplified group, none of the tumors had a level for p19 that was below the mean in the nonamplified group. Identification ofpl9 as theproduct ofnm23 gene. Our findings have prompted us to investigate the identity of p 19. Proteins in preparative 2-D gels of a neuroblastoma cell line were electroblotted onto glass fiber filters, and p19 spots were excised and applied directly onto a gas phase sequencer (16) . While another protein from these blots gave a known sequence, no sequence was generated for p19, suggesting that the NH2 terminus was blocked. This finding led us to pool p 19 polypeppJ9/nm23 Levels in Neuroblastoma 343 tide spots from preparative 2-D gels for internal sequencing. Tryptic cleavage fragments were separated by reversed phase HPLC (17) . The sequences of three peptides were determined and are shown in Fig. 3 . A protein data base search revealed a complete match of the three peptide sequences to nm23-H1 (1), which has been shown to be identical to the A subunit of NDP kinase in human red blood cells (9) . Because ofthe possibility that p19 could represent one of several forms of nm23 protein, this particular form is referred to as p19/nm23. Phosphorylation studies. Metabolic labeling ofa neuroblastoma cell line with [32P] inorganic phosphate was undertaken to determine the phosphorylation status ofp I 9/nm23. Autoradiographic analysis of 2-D gels revealed absence of a labeled spot in the position ofp 19. To rule out the occurrence ofother nm23 related proteins that could be reduced in advanced stage neuroblastoma, we undertook careful quantitative analysis of other proteins in the megawatt range of 15-20 kD in 2-D gels. The only polypeptides observed that were diminished in advanced stage neuroblastoma were unrelated to nm23 and represented phosphorylated forms of Opl 8, as previously reported (18) .
Reactivity ofpl 9 with an antibody to NDP kinase. A rabbit polyclonal antiserum against the A subunit of human NDP kinase (kindly provided by Dr. M. Veron, Pasteur Institute, Paris) was used for Western blot analysis ofneuroblastoma cell proteins separated by 2-D PAGE. The antiserum was used at a 1,000-fold dilution and reactivity was detected using goat antirabbit peroxidase conjugate. Analysis of samples from several tumors from different stages showed that the antibody preparation reacted strongly and exclusively with the p19 polypeptide spot. Thus modified forms of p19 such as might result from phosphorylation or cleavage were not detectable.
Southern blot analysis. To determine whether increased p19/nm23 levels in neuroblastoma tumors are associated with amplification of the nm23 gene, Southern blot analysis of 11 DNA samples from tumors from patients with high or low levels of p19/nm23 was done, using a 600-bp PstI fragment of pnm23, kindly provided by P. Steeg (1) . There was no evidence for gene rearrangement or amplification in any of the tumors. The possibility remains that nm23, as a kinase that generates GTP, could play a variety of roles depending on other factors which vary between cells and tumors. NDP kinases have been found to be associated with a variety ofGTP binding proteins, playing such roles as regulating the polymerization of microtubules and the function of G-proteins in signal transduction (21) . Thus, through their involvement in different cellular processes, they could promote cell proliferation as well as other cellular activities.
The findings to date pertaining to nm23 serve to illustrate the complex nature of the effect that expression of a particular gene could have on cellular processes. Elucidation ofthe mechanism by which nm23 could have distinct if not opposite roles in different tumors could contribute to our understanding of some ofthe complex processes leading to tumor heterogeneity.
